Savara Inc (NASDAQ:SVRA) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Savara Inc (NASDAQ:SVRA) have been given an average recommendation of “Moderate Buy” by the six ratings firms that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $8.83.

A number of research analysts recently weighed in on SVRA shares. Wells Fargo & Company started coverage on shares of Savara in a research note on Friday, December 20th. They issued an “overweight” rating and a $8.00 price target on the stock. JMP Securities reaffirmed a “market outperform” rating and issued a $9.00 price target on shares of Savara in a research note on Thursday, December 19th.

Savara Trading Down 1.4 %

SVRA stock opened at $2.82 on Monday. The company’s 50-day simple moving average is $2.73 and its 200-day simple moving average is $3.32. The company has a quick ratio of 17.70, a current ratio of 17.70 and a debt-to-equity ratio of 0.13. Savara has a 52-week low of $2.26 and a 52-week high of $5.34. The firm has a market cap of $483.97 million, a P/E ratio of -6.56 and a beta of 0.60.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of SVRA. Cibc World Markets Corp acquired a new stake in Savara in the 4th quarter valued at about $33,000. XTX Topco Ltd acquired a new stake in Savara in the 4th quarter valued at about $34,000. Ameriprise Financial Inc. acquired a new stake in Savara in the 4th quarter valued at about $37,000. KLP Kapitalforvaltning AS acquired a new stake in Savara in the 4th quarter valued at about $41,000. Finally, Hsbc Holdings PLC acquired a new stake in Savara in the 4th quarter valued at about $48,000. 87.93% of the stock is owned by hedge funds and other institutional investors.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.